Table 1.
Included study | Publication type | Country | Study design | Model design | Model cycle length | Time horizon | Cost perspective | Annual discount rate for health benefits (%) | Annual discount rate for costs (%) | Model health state |
---|---|---|---|---|---|---|---|---|---|---|
Kouroukis et al12 | Abstract | Canada | Cost-utility | Markov | Not reported | 50 years | Public health system | 5 | 5 | Progress free Progressive disease Death |
Mucha et al13 | Abstract | Poland | Cost-utility | Markov | Not reported | Lifetime | National Health Foundation | 4 | 5 | First-line Second-line Third-line Subsequent line Death |
Van Beurden-Tan et al14 | Abstract | Germany | Cost-effectiveness/utility | Markov | 1 month | Lifetime | Third payer | 3 | 3 | First-line Second-line Third-line Fourth-line Death |
Rickert et al15 | Abstract | Sweden | Cost-utility | Partitioned survival model | Not reported | 30 years | Public health system | Not reported | Not reported | Progress free Progressive disease Death |
Garrison et al16 | Full publication | USA | Cost-effectiveness/utility | Markov | 1 month | 20 years | Third payer | 3 | 3 | Stable disease Minor response Partial response Complete response Treatment free Progressive disease Second-line Death |
Oster et al17 | Abstract | USA | Cost-effectiveness/utility | Partitioned survival model | Not reported | Lifetime | Third payer | 3 | 3 | Progress free Progressive disease Death |
Picot et al18 | Full publication | UK | Cost-utility | Partitioned survival model | 6 weeks | 30 years | National health system | 4 | 4 | Treatment Posttreatment Progressive disease |
Yoong et al19 | Abstract | Canada | Cost-utility | Not reported | Not reported | 10 years | Public health system | Not reported | Not reported | Not reported |
Cavenagh et al20 | Abstract | USA | Cost-effectiveness/utility | Partitioned survival model | Not reported | Lifetime | US payer | 3 | 3 | Not reported |
Bagust et al21 | Abstract | UK | Cost-utility | Partitioned survival model | Not reported | Lifetime | National health system | 0 | 0 | Not reported |
Mehta et al22 | Full publication | USA | Cost-utility | Decision making tree | Not reported | Lifetime | Third payer | 0 | 0 | Not reported |
Felix et al23 | Abstract | Portugal | Cost-effectiveness/utility | Markov | Not reported | Lifetime | Public health system | 5 | 5 | Not reported |
Fragoulakis et al24 | Full publication | Greece | Cost-effectiveness/utility | Discrete event simulation | Not reported | Lifetime | Public health system | 4 | 4 | Partial response Complete response Stable disease Progressive disease |
Hornberger et al25 | Full publication | Sweden | Cost-effectiveness/utility | Partitioned survival model | 3 weeks | 10 years | Public health system | 3 | 3 | Progress free Progressive diseas Death |
Jiang et al26 | Abstract | UK | Cost-effectiveness/utility | Partitioned survival model | Not reported | Lifetime | National health system | 4 | 4 | Progressive free Progressive disease Death |
Liwing et al27 | Abstract | Nordic four countries (Finland, Norway, Sweden, Denmark) | Cost-effectiveness/utility | Partitioned survival model | Not reported | Lifetime | Public health system | Not reported | Not reported | Progress free Progressive disease Death |
Moller et al28 | Full publication | Norway | Cost-effectiveness/utility | Discrete event simulation | Not reported | 2 years | Public health system | 4 | 4 | Partial response Complete response Stable disease Progressive disease |